AI assistant
DEXCOM INC — Director's Dealing 2023
Mar 10, 2023
30198_dirs_2023-03-10_d52c0d62-6292-4a7c-8e75-96a2cfd6ad1d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-03-08
Reporting Person: Selvaraj Shelly Ramasamy (SVP Chief Information Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-03-08 | Common Stock | A | 10885 | $0.001 | Acquired | 60984 | Direct |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2: Included in this number are 26,736 unvested restricted stock units, 10,885 of which were granted on March 8, 2023 and shall all vest on March 8, 2026, 4,051 of which were granted on September 8, 2022 and shall all vest on September 8, 2023, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.